Vertex Pharmaceuticals, AbbVie, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that leverage living organisms, cells or molecular processes to develop drugs, therapies, diagnostics and other life-science products. These firms typically invest heavily in research and development and see their valuations swing dramatically based on clinical trial results, regulatory approvals or patent outcomes. As a result, biotech stocks offer the potential for substantial gains but also carry heightened risk compared with more mature industries. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of NASDAQ:VRTX traded down $5.87 during midday trading on Thursday, reaching $379.78. The company had a trading volume of 1,900,499 shares, compared to its average volume of 1,611,196. The company has a fifty day simple moving average of $453.73 and a two-hundred day simple moving average of $466.25. The firm has a market cap of $97.53 billion, a price-to-earnings ratio of 27.26 and a beta of 0.44. Vertex Pharmaceuticals has a 1-year low of $372.35 and a 1-year high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.52.
Read Our Latest Research Report on VRTX
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE:ABBV traded up $2.18 during trading hours on Thursday, hitting $198.48. 1,793,815 shares of the stock traded hands, compared to its average volume of 6,786,870. The company has a current ratio of 0.74, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. The firm has a market cap of $350.63 billion, a price-to-earnings ratio of 94.66, a PEG ratio of 1.27 and a beta of 0.50. The firm has a 50 day moving average price of $189.13 and a 200 day moving average price of $190.69. AbbVie has a fifty-two week low of $163.81 and a fifty-two week high of $218.66.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of Thermo Fisher Scientific stock traded up $3.75 on Thursday, hitting $452.69. 607,437 shares of the company traded hands, compared to its average volume of 2,512,195. The company has a market cap of $170.94 billion, a PE ratio of 26.23, a PEG ratio of 2.49 and a beta of 0.74. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average price of $424.58 and a 200 day moving average price of $465.66.
Read Our Latest Research Report on TMO
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
